Meanwhile, hemophilia A drug Altuviiio reached nearly a quarter of a billion euros in sales in the fourth quarter, with Sanofi crediting that growth to an increasing number of patients switching ...
Sobi’s Sanofi-partnered efanesoctocog alfa has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA ...
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Altuvoct (efanesoctocog alfa) to be used to ...
Hosted on MSN1mon
Sanofi Down 10% in 3 Months: How Should You Play the Stock?Sanofi’s new products like novel recombinant factor VIII therapy, Altuviiio, respiratory syncytial virus (RSV) antibody, Beyfortus (in partnership with AstraZeneca [AZN]), Pompe disease therapy ...
The Sanofi Global Health Unit plays an important ... And the second question, a very short one, given the current dynamics with ALTUVIIIO, is that one your next blockbuster and no later than ...
Sanofi’s sales rose 10% on a constant currency rate (“CER”) basis, while earnings per share declined 11%. Higher sales of Dupixent and contributions from new products like Altuviiio and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback